Oculis Holding AG (OCS) Non-Current Debt (2021 - 2022)
Oculis Holding AG's (OCS) quarterly Non-Current Debt came in at $127.1 million in Q4 2022, up 3.26% year-on-year from $123.1 million in Q4 2021, and up 3.26% quarter-over-quarter from $123.1 million in Q4 2021.
Oculis Holding AG (OCS) Non-Current Debt (2021 - 2022) Analysis & Trends
Oculis Holding AG's Non-Current Debt history runs 2 years deep, the most recent figure standing at $127.1 million for Q4 2022.
- On a quarterly basis, Non-Current Debt rose 3.26% year-over-year to $127.1 million in Q4 2022; TTM through Dec 2022 was $127.1 million, a 3.26% increase from a year earlier, with the FY2022 full-year figure at $128.4 million, up 3.34% from the prior year.
- Non-Current Debt grew to $127.1 million in Q4 2022 per OCS's latest filing, from $123.1 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $127.1 million in Q4 2022 and bottomed at $123.1 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 105.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 842.92 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 127.10 Mn |
| Dec 31, 2021 | 123.09 Mn |